GSK plc (NYSE:GSK – Free Report) – Stock analysts at Zacks Research lifted their Q4 2024 EPS estimates for shares of GSK in a report issued on Tuesday, June 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $0.84 per share for the quarter, up from their prior estimate of $0.83. The consensus estimate for GSK’s current full-year earnings is $4.11 per share. Zacks Research also issued estimates for GSK’s Q2 2025 earnings at $1.00 EPS.
GSK (NYSE:GSK – Get Free Report) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The company had revenue of $9.34 billion for the quarter, compared to analysts’ expectations of $8.98 billion.
Check Out Our Latest Stock Analysis on GSK
GSK Stock Down 0.4 %
GSK opened at $38.50 on Friday. The company has a market cap of $79.79 billion, a P/E ratio of 13.95, a P/E/G ratio of 1.17 and a beta of 0.66. GSK has a 12 month low of $33.67 and a 12 month high of $45.92. The business’s 50-day moving average price is $42.51 and its 200-day moving average price is $41.20. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a $0.3762 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.91%. GSK’s dividend payout ratio (DPR) is presently 53.26%.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its position in shares of GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 676 shares during the period. Register Financial Advisors LLC bought a new position in shares of GSK in the 1st quarter worth approximately $31,000. BKM Wealth Management LLC purchased a new position in shares of GSK in the 4th quarter valued at approximately $32,000. Richardson Financial Services Inc. bought a new stake in shares of GSK during the fourth quarter valued at approximately $40,000. Finally, Jones Financial Companies Lllp grew its stake in GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after purchasing an additional 509 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
- Five stocks we like better than GSK
- 3 Warren Buffett Stocks to Buy Now
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Use the MarketBeat Excel Dividend Calculator
- MarketBeat Week in Review – 6/24 – 6/28
- How Technical Indicators Can Help You Find Oversold Stocks
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.